CN115845125B - Glycyrrhizinc acid hydrogel loaded with tryptophan carbon quantum dots as well as preparation method and application thereof - Google Patents
Glycyrrhizinc acid hydrogel loaded with tryptophan carbon quantum dots as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN115845125B CN115845125B CN202211567680.6A CN202211567680A CN115845125B CN 115845125 B CN115845125 B CN 115845125B CN 202211567680 A CN202211567680 A CN 202211567680A CN 115845125 B CN115845125 B CN 115845125B
- Authority
- CN
- China
- Prior art keywords
- tryptophan
- carbon quantum
- glycyrrhizic acid
- quantum dots
- acid hydrogel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 title claims abstract description 141
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 title claims abstract description 141
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 title claims abstract description 132
- 239000000017 hydrogel Substances 0.000 title claims abstract description 103
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000002253 acid Substances 0.000 title description 4
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 126
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 122
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 122
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 122
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 122
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 122
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 122
- 239000012154 double-distilled water Substances 0.000 claims abstract description 14
- 238000001027 hydrothermal synthesis Methods 0.000 claims abstract description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 9
- 239000000600 sorbitol Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 6
- 238000006243 chemical reaction Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 101100011511 Mus musculus Elovl6 gene Proteins 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 238000001879 gelation Methods 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 3
- 206010061218 Inflammation Diseases 0.000 abstract description 3
- 229910052799 carbon Inorganic materials 0.000 abstract description 3
- 230000004054 inflammatory process Effects 0.000 abstract description 3
- 206010041925 Staphylococcal infections Diseases 0.000 abstract description 2
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 abstract description 2
- 238000001308 synthesis method Methods 0.000 abstract description 2
- 206010052428 Wound Diseases 0.000 description 33
- 208000027418 Wounds and injury Diseases 0.000 description 33
- 241000191967 Staphylococcus aureus Species 0.000 description 14
- 230000029663 wound healing Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 239000000499 gel Substances 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- RJQXTJLFIWVMTO-TYNCELHUSA-N Methicillin Chemical compound COC1=CC=CC(OC)=C1C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 RJQXTJLFIWVMTO-TYNCELHUSA-N 0.000 description 10
- 229960003085 meticillin Drugs 0.000 description 10
- 230000000694 effects Effects 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 208000035143 Bacterial infection Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 208000022362 bacterial infectious disease Diseases 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000006142 Luria-Bertani Agar Substances 0.000 description 4
- DIOIOSKKIYDRIQ-UHFFFAOYSA-N ciprofloxacin hydrochloride Chemical compound Cl.C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 DIOIOSKKIYDRIQ-UHFFFAOYSA-N 0.000 description 4
- 210000002889 endothelial cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000002096 quantum dot Substances 0.000 description 4
- 210000001626 skin fibroblast Anatomy 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000003606 umbilical vein Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 3
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 3
- 239000006137 Luria-Bertani broth Substances 0.000 description 3
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 229960001229 ciprofloxacin hydrochloride Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000010703 silicon Substances 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000032544 Cicatrix Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 231100000053 low toxicity Toxicity 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000037387 scars Effects 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000034309 Bacterial disease carrier Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- 208000037942 Methicillin-resistant Staphylococcus aureus infection Diseases 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 239000002086 nanomaterial Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001937 non-anti-biotic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000001338 self-assembly Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 150000003648 triterpenes Chemical group 0.000 description 1
- 238000004506 ultrasonic cleaning Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots, which comprises 1-4wt% of glycyrrhizic acid, 0.005-0.05wt% of tryptophan carbon quantum dots and the balance double distilled water. The preparation method comprises the following steps: dissolving tryptophan and sorbitol in double distilled water, transferring the mixture into a high-pressure reaction kettle for hydrothermal reaction to obtain a tryptophan carbon quantum dot solution; dissolving glycyrrhizic acid in double distilled water, adding tryptophan carbon quantum dot solution, stirring uniformly, centrifuging, and gelatinizing at room temperature to obtain the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots. The invention also discloses a glycyrrhizic acid hydrogel wound dressing based on the tryptophan-loaded carbon quantum dots. The glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots is prepared from two natural carbon sources of tryptophan and sorbitol by a one-step synthesis method, has good biocompatibility, low cost and simple preparation, and can effectively inhibit MRSA and inflammatory reaction.
Description
Technical Field
The invention belongs to the field of medicines, and particularly relates to a glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots, and a preparation method and application thereof.
Background
It is counted that millions of chronic wounds, caused by trauma, disease or surgery, need to be treated each year, and open, moist and exuding wounds provide a perfect environment for bacterial colonization by staphylococcus aureus, pseudomonas aeruginosa, streptococcus, etc., which is prone to wound infection. From ancient times, prevention of bacterial infection and anti-infection of wounds have been clinical challenges to be resolved in chronic wound therapy.
In the current clinical treatment, wound dressings such as gauze, adhesive bandages and the like can be used for absorbing tissue exudates and isolating the outside so as to achieve the aim of preventing bacterial infection of wounds. In addition, oral or intravenous antibiotics are the primary strategy for treating wounds from bacterial infections. However, with the large-scale and irrational use of antibiotics, drug-resistant strains are layered endlessly, resulting in a patient with prolonged wound and high mortality, with Methicillin-resistant staphylococcus aureus (MRSA) being the most harmful. Therefore, it is particularly important to find a novel non-antibiotic wound dressing with the antibacterial activity of methicillin staphylococcus aureus so as to promote the healing effect of chronic wounds.
In recent years, nanoparticles have become a replacement tool for controlling bacterial infection and overcoming antibiotic resistance due to their unique advantages of excellent physicochemical properties, such as high surface reactivity, ultra-small size, high water solubility, and good biocompatibility. However, they still have certain drawbacks: 1) Most of the nano particles belong to metal materials, and have high cost and high toxicity; 2) The preparation process is complex; 3) Toxicity problems, nanoparticles exert an antibacterial effect mainly by photodynamic to generate Reactive Oxygen Species (ROS), which can also cause irreversible damage to normal tissues; 4) The pure nanoparticle antibacterial agent is mostly in a liquid state, cannot serve as a wound dressing, and meets the advantages of absorbing tissue exudates and isolating the outside.
Disclosure of Invention
The invention aims to solve the technical problems and overcome the defects in the background art, and provides an glycyrrhizic acid hydrogel based on tryptophan carbon quantum dots, and a preparation method and application thereof.
In order to solve the technical problems, the technical scheme provided by the invention is as follows:
the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots comprises the following components in percentage by mass: 1-4wt% of glycyrrhizic acid, 0.005-0.05wt% of tryptophan carbon quantum dots and the balance double distilled water.
Glycyrrhizic acid is used as the index component with highest content in Glycyrrhrizae radix, and accounts for 3.63% -13.06% of the total extract, and consists of hydrophobic 18β -glycyrrhetinic acid and two hydrophilic glucuronic acids. The natural glycyrrhizic acid molecules are arranged on the outer side by hydrophilic glucosyl groups in water, the hydrophobic triterpene skeleton is arranged on the inner side, the natural glycyrrhizic acid molecules are self-assembled in water to form right-handed spiral fibers, and the glycyrrhizic acid fibers are further wound to finally form a hydrogel network structure; besides unique physical and chemical functional characteristics, the glycyrrhizic acid has a drug absorption enhancing effect and an anti-multi-drug resistance mechanism, can be used as a carrier material in a drug delivery system, has multiple effects of resisting viruses, inflammation, bacteria and the like, and can particularly play an anti-MRSA activity role by inhibiting the formation of a biological film. Therefore, the invention adopts glycyrrhizic acid as a carrier to encapsulate the tryptophan carbon quantum dots, and the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots can obviously accelerate the wound healing of mice with MRSA infection model.
As a general inventive concept, the present invention also provides a preparation method of the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots, comprising the following steps:
(1) Dissolving tryptophan and sorbitol in double distilled water, uniformly mixing, transferring the mixture into a high-pressure reaction kettle for hydrothermal reaction, and obtaining a tryptophan carbon quantum dot solution after the hydrothermal reaction is completed;
(2) Dissolving glycyrrhizic acid in double distilled water, adding the tryptophan carbon quantum dot solution prepared in the step (1), uniformly stirring, centrifuging, and then placing the mixture in room temperature for gelation to obtain the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots.
In the above preparation method, preferably, in the step (1), the mass ratio of tryptophan to sorbitol is 1:5.
In the preparation method, preferably, in the step (1), the temperature of the hydrothermal reaction is 100-200 ℃, and the time of the hydrothermal reaction is 10-20h.
In the above preparation method, preferably, in the step (2), the rotational speed of centrifugation is 3000-5000rpm, and the centrifugation time is 5-10min.
In the above preparation method, preferably, in the step (2), the gelation time is 5 to 10min.
The invention also provides a glycyrrhizic acid hydrogel wound dressing based on the tryptophan carbon quantum dot, which is prepared from the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dot or prepared by the preparation method.
Compared with the prior art, the invention has the advantages that:
(1) The glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots is prepared from two natural carbon sources of tryptophan and sorbitol by a one-step synthesis method, has good biocompatibility, low cost and simple preparation, and can effectively inhibit MRSA and inflammatory reaction.
(2) The glycyrrhizic acid adopted in the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots is easy to obtain, low in cost, degradable, good in biocompatibility and capable of forming a structural element of a supermolecule assembly, the glycyrrhizic acid hydrogel is used as a carrier to encapsulate the tryptophan carbon quantum dots, and the prepared hydrogel can obviously accelerate wound healing of mice infected by MRSA.
(3) The glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots has low toxicity and simple preparation process.
(4) The glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots is an injectable active wound dressing with good self-healing property, and has great clinical value; the wound dressing not only meets the main functions of absorbing tissue exudates and isolating the wound area from the outside through covering, but also can load tryptophan carbon quantum dots with high-efficiency MRSA and anti-inflammatory properties and achieve the purpose of completely releasing microenvironment which really influences the wound; more importantly, the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots combines the characteristics of antibacterial property of glycyrrhizic acid and tryptophan carbon quantum dots, plays a synergistic effect in inhibiting the activity of MRSA, and obviously promotes the healing of mice infected by the MRSA.
Drawings
FIG. 1 is an evaluation of erythrocyte hemolysis of tryptophan carbon quantum dots;
FIG. 2 is a graph of the cytotoxicity of tryptophan carbon quantum dots evaluated by CCK8 method: (a) Human umbilical vein endothelial cells, (b) human skin fibroblasts;
FIG. 3 is an electron microscope image of a hydrogel of glycyrrhizic acid and an aqueous gel of glycyrrhizic acid loaded with tryptophan carbon quantum dots prepared in the examples of the invention;
FIGS. 4 to 7 are rheological characterization diagrams of hydrogels of glycyrrhizic acid and the tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogels prepared in the examples of the present invention;
fig. 8 is a self-healing evaluation chart of an aqueous glycyrrhizic acid gel loaded with tryptophan carbon quantum dots prepared in the example of the invention;
FIG. 9 is an evaluation chart of injectability of an aqueous glycyrrhizic acid gel loaded with tryptophan carbon quantum dots prepared in the example of the invention;
FIG. 10 is an in vitro antimicrobial evaluation graph of tryptophan carbon quantum dots;
FIG. 11 is an antibacterial action diagram of an aqueous glycyrrhizic acid gel loaded with tryptophan carbon quantum dots in an embodiment of the invention;
FIG. 12 is a graph showing the cumulative release of tryptophan carbon quantum dots from an aqueous glycyrrhizic acid gel loaded with tryptophan carbon quantum dots according to an embodiment of the invention;
fig. 13 is a graph showing that the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots promotes wound healing in mice infected with MASR wound model according to an embodiment of the invention: (A) Schematic representation of the course of treatment in mice infected with MASR wound model; (B) taking a photo to record wound healing; (C) wound healing area rate for different treatment groups.
Detailed Description
The invention will be described more fully hereinafter with reference to the accompanying drawings and preferred embodiments in order to facilitate an understanding of the invention, but the scope of the invention is not limited to the following specific embodiments.
Unless defined otherwise, all technical and scientific terms used hereinafter have the same meaning as commonly understood by one of ordinary skill in the art. The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the scope of the present invention.
Unless otherwise specifically indicated, the various raw materials, reagents, instruments, equipment and the like used in the present invention are commercially available or may be prepared by existing methods.
According to the invention, two natural carbon sources of tryptophan and sorbitol are used as raw materials to synthesize the carbon quantum dots, and then the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots is synthesized, so that the hydrogel is found to have efficient antibacterial and anti-inflammatory effects. Previous studies have found that hydrogel wound dressings based on tryptophan carbon quantum dots can significantly accelerate wound healing in MRSA infected model mice.
Detection of biocompatibility and toxicity of tryptophan carbon quantum dots
The specific process for detecting the biocompatibility and toxicity of the tryptophan carbon quantum dots comprises the following steps:
(1) Tryptophan carbon quantum dot biocompatibility was assessed with a hemolysis assay: the hemolysis test was performed with patient consent (Xiangya Hospital at the university of south China). The erythrocytes were centrifuged at 1000rpm for 5min and washed 2 times to prepare a 20% erythrocyte suspension; thereafter, erythrocytes with or without tryptophan carbon quantum dot solutions (0, 25, 50, 100 and 200. Mu.g/mL) were prepared, double distilled water (ddH 2 O) treatment of erythrocytes as positive control, physiological saline treatment of erythrocytes as negative control, and co-incubation at 37 ℃ for 3h. Finally, the red blood cell suspension was centrifuged at 1000rpm for 5min, and the absorbance of the supernatant at 540nm (OD 540 nm) was measured, and the percent hemolysis was calculated as follows: hemolysis (%) = OD540 tryptophan carbon quantum dot/OD 540ddH 2 O×100％。
(2) Toxicity detection is carried out on tryptophan carbon quantum dots by using a CCK8 method: human umbilical vein endothelial cells and human skin fibroblasts were seeded at a density of 8×103/well in 96-well plates overnight, treated with tryptophan carbon quantum dots (1, 5, 10, 50, 100 and 200 ug/ml) at different volume concentrations, phosphate Buffered Saline (PBS) as control group, and cell-free medium as blank. 37 ℃ and 5% CO 2 Incubation was carried out for 24h with 10 μl CCK8 solution added to each well and incubated for 2h. Finally, cell viability was determined by measuring absorbance at 450nm (OD 450 nm) as follows: survival of lysocells (%) =od 450 colorAmino acid carbon quantum dot/OD 450PBS×100%.
As shown in FIG. 1, erythrocytes in ddH 2 Cracking in O; while erythrocytes treated with tryptophan carbon quantum dots at different concentrations did not show obvious hemolysis. Calculated, the hemolysis rate of the tryptophan carbon quantum dot at 200ug/mL is about 1.67 percent<5 percent), the tryptophan carbon quantum dots have good blood compatibility.
As shown in FIG. 2, the survival rate of human umbilical vein endothelial cells and human skin fibroblasts still exceeds 80% when tryptophan carbon quantum dot concentration is as high as 200ug/mL (far above minimum inhibitory concentration, MIC). This suggests that tryptophan carbon quantum dots have only very low toxicity to human umbilical vein endothelial cells and human skin fibroblasts. Therefore, tryptophan carbon quantum dots are a novel nano material with great potential in the field of medical treatment.
Examples:
the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots comprises the following components in percentage by mass: about 3.2wt% glycyrrhizic acid, about 0.01wt% tryptophan carbon quantum dots and the balance double distilled water.
The preparation method of the glycyrrhizic acid hydrogel and the tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel in the embodiment comprises the following steps:
(1) Dissolving 100mg tryptophan (0.49 mmol) and 500mg sorbitol (2.74 mmol) in 50mL double distilled water, fully and uniformly mixing, then subpackaging the mixture into 5mL ampoules, sealing the ampoules, transferring the ampoules into a high-pressure reaction kettle, carrying out hydrothermal reaction for 10 hours at 160 ℃, cooling to room temperature to obtain tryptophan carbon quantum dot solution, detecting the concentration to be 1mg/mL, and storing the ampoule bottles at 4 ℃;
(2) Dissolving 0.03g of glycyrrhizic acid in 900ul double distilled water, standing at 60 ℃ for 10min to completely dissolve the glycyrrhizic acid, adding 100ul tryptophan carbon quantum dot solution prepared in the step (1), stirring and mixing uniformly, centrifuging at 3000rpm for 5min to remove bubbles, standing at room temperature for 10min to gel, and obtaining the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots.
For comparison, 0.03g of glycyrrhizic acid was dissolved in 1000ul of double distilled water, and the mixture was left at 60℃for 10min to completely dissolve, followed by cooling to obtain glycyrrhizic acid hydrogel.
The silicon wafer is firstly ultrasonically cleaned for 15min by using mixed solution (concentrated sulfuric acid (V): hydrogen peroxide (V) =7:3), then ultrasonically cleaned for 15min by using ethanol, and finally is ultrasonically cleaned by using ddH 2 Ultrasonic cleaning for 15min (2 times), and drying the silicon wafer by nitrogen; 10ul of the glycyrrhizic acid hydrogel and the tryptophan carbon quantum dot-loaded glycyrrhizic acid hydrogel prepared in the embodiment are taken out and respectively put on a dried silicon wafer, and then are put into a freeze dryer for drying for 12h, and then are subjected to electron microscope scanning, and the result is shown in figure 3.
As can be seen from fig. 3, both the glycyrrhizic acid hydrogel and the tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel show an irregular loose porous network structure, and the pore diameter ranges from 20 μm to 200 μm, which indicates that the carbon quantum dots can be loaded in the hydrogel network, and provides conditions for releasing the carbon quantum dots. Compared with glycyrrhizic acid hydrogel, the porous structure of the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots is compact, which indicates that the tryptophan carbon quantum dots have influence on the glycyrrhizic acid self-assembly process after being added.
The dynamic viscoelasticity test of the glycyrrhizic acid hydrogel and the tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel prepared in the embodiment comprises the following specific steps:
(1) Dynamic frequency sweep: placing glycyrrhizic acid hydrogel and tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel on a rheometer sample stage, selecting a dynamic frequency scanning mode, setting the temperature to 25 ℃, the strain to 0.5%, and the angular frequency to 0.1-100rad/s, wherein the result is shown in figure 4;
(2) Strain scanning: placing the glycyrrhizic acid hydrogel and the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots on a rheometer sample table, selecting a dynamic strain scanning mode, setting the temperature to 25 ℃, and setting the strain to 1-1000% and the angular frequency to 1rad/s, wherein the result is shown in figure 5;
(3) Cyclic step-strain sweep: placing the glycyrrhizic acid hydrogel and the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots on a rheometer sample table, selecting a cyclic step strain scanning mode, setting the temperature to 25 ℃, setting the angular frequency to 1rad/s, setting the low strain to 1%, setting the angular frequency to 120s, setting the high strain to 100% and setting the angular frequency to 120s, and setting the results to be shown in a figure 6;
(4) And (5) viscosity scanning: placing the single glycyrrhizic acid hydrogel and the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots on a rheometer sample stage, selecting a steady-state viscosity scanning mode, setting the temperature to 25 ℃ and the shear rate to 0.1-100s -1 、100-0.1s -1 The strain was 0.5% and the angular frequency was 1rad/s, and the results are shown in FIG. 7.
As shown in fig. 4, the storage modulus (G') was always higher than the loss modulus (G ") in the measurement range, and the glycyrrhizic acid hydrogel and the tryptophan carbon quantum dot-loaded glycyrrhizic acid hydrogel mainly exhibited elastic properties, indicating that stable elastic hydrogels were formed. As the angular frequency increases, the storage modulus and the loss modulus show an ascending trend, which shows that the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots has frequency dependence like that of the glycyrrhizic acid hydrogel, and accords with the physical dynamic crosslinking of hydrophobic association and chain entanglement of the main crosslinking effect of the hydrogel network. The intersection of the storage modulus (G ') and loss modulus (G') indicates shear failure of the internal network of the hydrogel. Fig. 5 shows that the network structure of the glycyrrhizic acid hydrogel and the tryptophan-loaded carbon quantum dots is broken by shear at strains of 50% and 200%. Step strain tests (FIG. 6) show that at low strain of 1%, G 'is higher than G'; at high strains of 1000%, G 'is lower than G'. After three transitions from high strain to low strain, the glycyrrhizic acid hydrogel and the tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel decrease with increasing frequency, but can still well recover to the hydrogel state, which indicates that the tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel has good self-healing property. Fig. 7 shows the relationship between viscosity and shear rate, and the decrease in the glycyrrhizic acid hydrogel and the tryptophan carbon quantum dot-loaded glycyrrhizic acid hydrogel with increasing shear rate, indicating that the microstructure of the hydrogel is damaged by shear thinning. As the shear rate decreases, the damaged tissue gradually returns to its original state, indicating that the hydrogel has good injectability. The G 'and G' of the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots are always higher than that of the glycyrrhizic acid hydrogel, so that the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots has better mechanical strength performance than that of the glycyrrhizic acid hydrogel, and the tryptophan carbon quantum dots further promote the formation of the network structure of the glycyrrhizic acid hydrogel.
Further observing the self-healing property of the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots, which is prepared by the embodiment, the specific test steps are as follows:
(1) Respectively placing the mixed solution of the loaded tryptophan carbon quantum dots added with the coomassie brilliant blue and the mixed solution of the loaded tryptophan carbon quantum dots without the coomassie brilliant blue in two cylindrical molds, and cooling into white and blue glycyrrhizic acid aqueous gels loaded with the tryptophan carbon quantum dots;
(2) The two glycyrrhizic acid aqueous gels loaded with the tryptophan carbon quantum dots are sheared into two halves, then the white glycyrrhizic acid aqueous gel loaded with the tryptophan carbon quantum dots and the blue glycyrrhizic acid aqueous gel loaded with the tryptophan carbon quantum dots are spliced together, healing conditions between the two halves of glycyrrhizic acid aqueous gels loaded with the tryptophan carbon quantum dots are observed every 2 hours, and the result is shown in fig. 8, so that the glycyrrhizic acid aqueous gel loaded with the tryptophan carbon quantum dots has good self-healing property.
The injectability of the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots prepared in the embodiment is observed, and the specific test steps are as follows:
the heated mixed solution of the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots is sucked by a 1mL syringe, and the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots is injected through a pinhole after being cooled, as shown in fig. 9, so that the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots has good injectability.
The antibacterial effect of tryptophan carbon quantum dots and the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots prepared in the embodiment is detected, and the specific detection steps are as follows:
(1) Inhibition of tryptophan carbon Quantum dots against Staphylococcus aureus-sensitive strains (ATCC 25923, ATCC 29213), methicillin-resistant Staphylococcus aureus strains (ATCC 43300, 222125587 and 223116824), pseudomonas aeruginosa strains (ATCC 27853), escherichia coli (ATCC 25922) and Klebsiella pneumoniae (ATCC 700603) by LB broth methodUsing: taking 1×10 6 CFU ml -1 The bacterial viability was determined by measuring the absorbance at 600nm (OD 600 nm) after 12h of treatment with 100ul of Phosphate Buffer (PBS) as untreated group, spread on 96 well plates and treated with tryptophan carbon quantum dots of different volume concentrations;
(2) Inhibition efficiency of the untreated group, tryptophan quantum dot group, glycyrrhizic acid group and tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel group against methicillin-resistant staphylococcus aureus strains (ATCC 43300 and 222125587) was compared with LB broth method: taking 1×10 6 CFU ml -1 Is spread on a 96-well plate, and is treated by a tryptophan quantum dot group (40 ug/ml), a glycyrrhizic acid group (1.6 mg/ml) and an glycyrrhizic acid hydrogel group loaded with tryptophan carbon quantum dots (40 ug/ml+1.6mg/ml), phosphate Buffer (PBS) is used as a blank control, the final volume of each well is 100ul, and after 12 hours of treatment, the bacterial survival rate is determined by measuring the absorbance at 600nm (OD 600 nm);
(3) The inhibition efficiency of untreated groups, tryptophan quantum dot groups, glycyrrhizic acid groups and glycyrrhizic acid hydrogel groups loaded with tryptophan carbon quantum dots on methicillin-resistant staphylococcus aureus strains is compared by an LB agar plate method: 20ul of bacterial suspension (1X 10) 6 CFU ml -1 ) Dissolving in LB agar containing tryptophan quantum dot group (40 ug/ml), glycyrrhizic acid group (1.6 mg/ml) and glycyrrhizic acid hydrogel group loaded with tryptophan carbon quantum dots (40 ug/ml+1.6mg/ml), mixing thoroughly, pouring into a flat plate, and controlling the temperature of LB agar (40-50 ℃) in the process, wherein bacteria cannot be easily scalded too high, and LB cannot be easily coagulated too low; after 12h incubation at 37℃LB agar plates were photographed.
As shown in FIG. 10, tryptophan carbon quantum dots can remarkably inhibit the activity of staphylococcus aureus sensitive strains and methicillin-resistant staphylococcus aureus strains, and show weak sensitivity to gram-negative bacteria such as pseudomonas aeruginosa, escherichia coli and klebsiella pneumoniae.
As shown in fig. 11, both the LB broth method and the LB agar plate method show that the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots has a more remarkable effect than the tryptophan carbon quantum dots or glycyrrhizic acid alone in inhibiting the activity of the methicillin-resistant staphylococcus aureus strain.
These results demonstrate that tryptophan carbon quantum dots have excellent antibacterial activity against staphylococcus aureus-sensitive strains and methicillin-resistant staphylococcus aureus strains, and that the glycyrrhizic acid hydrogel formed by combining with glycyrrhizic acid and loaded with tryptophan carbon quantum dots has a synergistic effect in resisting the activity of methicillin-resistant staphylococcus aureus strains.
The in vitro release of tryptophan carbon quantum dots in the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots is detected by an enzyme-labeled instrument, and the specific steps are as follows:
(1) Adding 2mL of glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots and prepared by the preparation method of the embodiment into a 5mL brown glass sample bottle, then adding PBS (pH= 7.4,0.01M) with the same volume as a slow release solution, and placing the whole slow release system into a constant temperature shaking table (100 rpm) at 37 ℃;
(2) Taking 400 mu L of slow-release liquid out at preset time points (2, 4,8, 10, 20, 24, 36 and 48 h), adding 400 mu L of fresh PBS for continuous slow release, centrifuging the taken slow-release liquid at 3000rpm and 4 ℃ for 15min, collecting supernatant, and preserving at 4 ℃;
(3) The cumulative release of tryptophan carbon quantum dots in the supernatant was measured by measuring absorbance at 470nm (OD 470 nm) (based on the linear relationship between OD470nm and tryptophan carbon quantum dot concentration), and the results are shown in fig. 12.
As can be seen from fig. 12, the tryptophan carbon quantum dots in the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots are gradually released and completely released within 2 days, which indicates that the glycyrrhizic acid hydrogel is an ideal loading system for the tryptophan carbon quantum dots, and the tryptophan carbon quantum dots are promoted to exert the antibacterial and anti-inflammatory effects permanently.
Application of glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots:
tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel prepared in the examples was used as a wound dressing to promote wound healing in Methicillin Resistant Staphylococcus Aureus (MRSA) infected wound model mice, BALB/c mice (40, 22±0.5 g) were purchased from cavus hundred model animal research co (su zhou) and experiments were started after 1 week of adaptation. All animal experiments were approved by the ethical committee of the xiangya hospital at the university of south China. A schematic of the course of treatment of MASR-infected wound model mice is shown in FIG. 13 (A), and the specific steps are as follows:
(1) Establishment of a full-thickness skin wound model of a mouse: isoflurane anesthetized mice, shaved and disinfected on the backs, and a round full-layer wound surface with the diameter of 0.6cm is cut by using a puncher;
(2) Establishment of a mouse MASR infection wound model: after the above operation, 20ul of 3.5X10 were added 8 CFU mL -1 Is dripped on the wound surface;
(3) After its slow absorption, 40 mice were randomized into group treatment: untreated group (10 mice), ciprofloxacin hydrochloride (10 mice), glycyrrhizic acid hydrogel group (10 mice) and glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots (10 mice) were applied once a day for 14 consecutive days;
(4) Observation, calculation and treatment of wound healing process: wound healing was recorded with photographs taken on days 1, 5, 10 and 15 of treatment, as shown in fig. 13 (B), photographs were processed using Image J software, wound areas at each time point were recorded, and wound healing rates were calculated using the following formula: wound healing rate = (initial wound area-treatment time point wound area)/initial wound area 100%, wound healing effect was evaluated, and the result is shown in fig. 13 (C).
As can be seen from fig. 13, the mice developed large-area abscesses 48h after bacterial infection; after 5 days of treatment, significant scab appeared after treatment with ciprofloxacin hydrochloride, tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel and alone glycyrrhizic acid hydrogel, while the untreated group remained full of pus and exudates. After 10 days of treatment, the wound is basically healed after being treated by glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots, the skin around the wound is in good state, and no ulceration or hypertrophic scars are observed; while ciprofloxacin hydrochloride (CH-stream) and alone glycyrrhizic acid hydrogel still had obvious hypertrophic scars, and the untreated group can observe the skin around the mouth to appear ulcerations. After 15 days of treatment, the healing areas of the untreated group, the ciprofloxacin hydrochloride group, the glycyrrhizic acid hydrogel group and the tryptophan carbon quantum dot loaded glycyrrhizic acid hydrogel group are calculated to be 68+/-1.86%, 87.7+/-4.5% and 76.8+/-7.2% and 96.2+/-2.7% respectively. From this, it can be seen that the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots as a wound dressing is beneficial to promoting wound healing of MASR infection.
Claims (5)
1. The application of the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots in preparing wound dressing for treating MASR infection is characterized in that,
the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots comprises the following components in percentage by mass: 3.2wt% of glycyrrhizic acid, 0.01wt% of tryptophan carbon quantum dots and the balance of double distilled water;
the preparation method of the glycyrrhizic acid hydrogel loaded with tryptophan carbon quantum dots comprises the following steps:
(1) Dissolving tryptophan and sorbitol in double distilled water, uniformly mixing, transferring the mixture into a high-pressure reaction kettle for hydrothermal reaction, and obtaining a tryptophan carbon quantum dot solution after the hydrothermal reaction is completed;
(2) Dissolving glycyrrhizic acid in double distilled water, adding the tryptophan carbon quantum dot solution prepared in the step (1), uniformly stirring, centrifuging, and then placing the mixture in room temperature for gelation to obtain the glycyrrhizic acid hydrogel loaded with the tryptophan carbon quantum dots.
2. The use according to claim 1, wherein in step (1) the mass ratio of tryptophan to sorbitol is 1:5.
3. The use according to claim 1, wherein in step (1) the temperature of the hydrothermal reaction is 100-200 ℃ and the time of the hydrothermal reaction is 10-20h.
4. The use according to claim 1, wherein in step (2), the rotational speed of centrifugation is 3000-5000rpm and the time of centrifugation is 5-10min.
5. The use according to claim 1, wherein in step (2) the gelation time is 5-10min.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211567680.6A CN115845125B (en) | 2022-12-07 | 2022-12-07 | Glycyrrhizinc acid hydrogel loaded with tryptophan carbon quantum dots as well as preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211567680.6A CN115845125B (en) | 2022-12-07 | 2022-12-07 | Glycyrrhizinc acid hydrogel loaded with tryptophan carbon quantum dots as well as preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115845125A CN115845125A (en) | 2023-03-28 |
| CN115845125B true CN115845125B (en) | 2024-02-20 |
Family
ID=85670931
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211567680.6A Active CN115845125B (en) | 2022-12-07 | 2022-12-07 | Glycyrrhizinc acid hydrogel loaded with tryptophan carbon quantum dots as well as preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115845125B (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110577581A (en) * | 2018-06-07 | 2019-12-17 | 美国蓝博药业公司 | Novel antibacterial lipopeptide compound, preparation method and application thereof |
| AU2020103459A4 (en) * | 2020-10-20 | 2021-01-28 | Hubei University | Preparation method and application of fluorescent hydrogel dressing |
| CN113332161A (en) * | 2021-04-06 | 2021-09-03 | 伊美莱(广州)医疗技术有限公司 | Ammonium glycyrrhetate hydrogel as well as preparation method and application thereof |
| CN113817181A (en) * | 2021-09-18 | 2021-12-21 | 西北大学 | Carbon quantum dot modified double-network hydrogel and preparation method thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4021476A4 (en) * | 2019-08-29 | 2023-10-11 | AJK Biopharmaceutical, LLC | Synthetic antimicrobial peptides |
-
2022
- 2022-12-07 CN CN202211567680.6A patent/CN115845125B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110577581A (en) * | 2018-06-07 | 2019-12-17 | 美国蓝博药业公司 | Novel antibacterial lipopeptide compound, preparation method and application thereof |
| AU2020103459A4 (en) * | 2020-10-20 | 2021-01-28 | Hubei University | Preparation method and application of fluorescent hydrogel dressing |
| CN113332161A (en) * | 2021-04-06 | 2021-09-03 | 伊美莱(广州)医疗技术有限公司 | Ammonium glycyrrhetate hydrogel as well as preparation method and application thereof |
| CN113817181A (en) * | 2021-09-18 | 2021-12-21 | 西北大学 | Carbon quantum dot modified double-network hydrogel and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| Antibacterial Amino Acid-Based Poly(ionic liquid) Membranes:Effects of Chirality, Chemical Bonding Type, and Application for MRSA Skin Infections;Jiangna Guo et al.;《ACS Applied Bio Materials》(第2期);第4418页前言第二段 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115845125A (en) | 2023-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Jiang et al. | Controlled release of silver ions from AgNPs using a hydrogel based on konjac glucomannan and chitosan for infected wounds | |
| CN105778126B (en) | Genipin cross-linked biogel and preparation method and application thereof | |
| Qian et al. | Dual cross-linked organic-inorganic hybrid hydrogels accelerate diabetic skin wound healing | |
| CN110314242B (en) | Preparation method and application of controlled-release antibiotic composite hydrogel | |
| CN108126237B (en) | Silver sulfadiazine temperature-sensitive gel and preparation method and application thereof | |
| CN112957457B (en) | Cascade enzyme-like nano system for promoting diabetic wound healing and preparation method and application thereof | |
| CN115124738B (en) | Double-layer bionic drug-loaded hydrogel and preparation and application thereof | |
| CN113214507B (en) | Preparation method of antibacterial glycopeptide hydrogel | |
| US20170312221A1 (en) | Pharmaceutical preparation and method of its production and use | |
| Gong et al. | Construction of a sustained-release hydrogel using gallic acid and lysozyme with antimicrobial properties for wound treatment | |
| Karydis-Messinis et al. | Development, physicochemical characterization and in vitro evaluation of chitosan-fish gelatin-glycerol hydrogel membranes for wound treatment applications. | |
| RU2699362C2 (en) | Composition based on cerium dioxide nanoparticles and brown algae polysaccharides for treating wounds | |
| WO2020180202A1 (en) | Composition based on cerium dioxide nanoparticles and brown algae polysaccharides for wound treatment | |
| Song et al. | Chitosan/poly (3-hydroxy butyric acid-co-3-hydroxy valeric acid) electrospun nanofibers with cephradine for superficial incisional skin wound infection management | |
| CN113509591A (en) | Antibacterial cationic injectable hydrogel dressing and preparation method thereof | |
| CN115845125B (en) | Glycyrrhizinc acid hydrogel loaded with tryptophan carbon quantum dots as well as preparation method and application thereof | |
| Chen et al. | A novel wound dressing based on a gold nanoparticle self-assembled hydrogel to promote wound healing | |
| CN111184906B (en) | PVA-based liquid dressing and preparation method thereof | |
| CN112980003A (en) | Natural polysaccharide based antibacterial hydrogel, preparation method and application | |
| Perchyonok et al. | Insights into functional tetracycline/antioxidant containing chitosan hydrogels as potential bio-active restorative materials: structure, function and antimicrobial activity | |
| CN115382008B (en) | Preparation method of injectable hydrogel suitable for diabetic wound repair | |
| CN108354951B (en) | Oxygen-enriched gel for promoting wound healing, preparation method and application | |
| EP3215129A2 (en) | Pharmaceutical preparation and method of its production and use | |
| Lu et al. | Multifunctional carbon quantum dots decorated self-healing hydrogel for highly effective treatment of superbug infected wounds | |
| Shen et al. | Preparation of nano-silver dressing for application on postoperative rehabilitation nursing of patients with gastrointestinal surgery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |